T. Schneider / Shutterstock.com

5 November 2024NewsAmericasSarah Speight

Sandoz lands reduced antitrust award of $70m

A US biopharma firm must pay the damages to Sandoz over a long-running dispute over lung therapy | New Jersey district judge had ordered the pair to “meet and confer” in a September judgment, but the parties couldn’t agree.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech